![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Ege University Pfizer |
---|---|
Information provided by: | Ege University |
ClinicalTrials.gov Identifier: | NCT00481364 |
This prospective, randomized, controlled study aims to investigate the effects of atorvastatin treatment in hemodialysis patients concerning progression of coronary artery calcification, progression of carotid artery intima-media thickness, endothelial function, and inflammation.
Condition | Intervention | Phase |
---|---|---|
Vascular Calcification Atherosclerosis Dyslipidemia Inflammation |
Drug: atorvastatin Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study |
Estimated Enrollment: | 446 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | August 2008 |
Estimated Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Atorvastatin 40 mg/day
|
Drug: atorvastatin
atorvastatin 40 mg/day
|
2: Placebo Comparator
placebo
|
Drug: placebo
1 tb/day
|
The effects of statin treatment on coronary artery calcifications, carotid artery intima-media thickness, and endothelial functions have never been investigated in hemodialysis patients. Regarding inflammation, the present data in hemodialysis patients are derived from small studies with short follow-up. We postulate that atorvastatin would reduce progression of coronary calcification and carotid artery intima-media thickness, decrease inflammation, and improve endothelial function. In this prospective, controlled, randomized study, four hundred forty-six prevalent hemodialysis patients who meet inclusion and exclusion criteria will be randomized to atorvastatin(20 mg/day in first month; increased to 40 mg/day afterwards) and placebo arms (each arm consists of 223 patients), after completion of baseline investigations. Randomization will be performed with random permuted blocks and will be stratified according to dialysis center, age, sex, diabetic status, duration of dialysis, high flux dialyser use, and dialysate calcium level. Follow-up period will be twelve months.
It is estimated that 446 patients would provide 90% power with a two-sided, alpha error rate of 5%, of detecting a significant difference between treatment arms. Dropout rate is expected to be 20%, not to be replaced.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Turkey, Izmir | |
Ege University School of Medicine, Division of Nephrology | |
Bornova, Izmir, Turkey, 35100 |
Principal Investigator: | Ercan Ok, MD | Ege University, Division of Nephrology |
Responsible Party: | Prof.Dr.Ercan Ok, Ege University Division of Nephrology ( Ege University ) |
Study ID Numbers: | 06-4.1/2 |
Study First Received: | May 30, 2007 |
Last Updated: | June 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00481364 History of Changes |
Health Authority: | Turkey: Ministry of Health |
hemodialysis endothelial function coronary artery calcification atherosclerosis statin |
Antimetabolites Atherosclerosis Arterial Occlusive Diseases Metabolic Diseases Antilipemic Agents Disease Progression Vascular Diseases Arteriosclerosis |
Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Inflammation Metabolic Disorder Dyslipidemias Atorvastatin Lipid Metabolism Disorders |
Antimetabolites Atherosclerosis Arterial Occlusive Diseases Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Vascular Diseases Enzyme Inhibitors Arteriosclerosis Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Inflammation Pathologic Processes Therapeutic Uses Cardiovascular Diseases Dyslipidemias Atorvastatin Lipid Metabolism Disorders |